Agile Therapeutics Inc (AGRX) SEC Filing 8-K Material Event for the period ending Thursday, April 30, 2020

Agile Therapeutics Inc

CIK: 1261249 Ticker: AGRX

View differences made from one to another to evaluate Agile Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Agile Therapeutics Inc.


Assess how Agile Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Agile Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: AGRX
CIK: 1261249
Form Type: 8-K Corporate News
Accession Number: 0001558370-20-005100
Submitted to the SEC: Tue May 05 2020 8:00:24 AM EST
Accepted by the SEC: Tue May 05 2020
Period: Thursday, April 30, 2020
Industry: Pharmaceutical Preparations
  1. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: